Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Viral Recombination

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Foot-and-mouth disease virus 3C protease as virulence determinant plays multiple roles in cleaving viral polyprotein and host factors.

Virulence·2025

Same author

Virulence determinant of Senecavirus A: 3C protein functions as a protease to cleave viral polyprotein and host factors.

Virulence·2025

Same author

Commentary: Development and immunogenicity evaluation of a quadruple-gene-deleted pseudorabies virus strain.

Frontiers in microbiology·2025

Same author

Establishment and Implementation of the Point-of-Care RT-RAA-CRISPR/Cas13a Diagnostic Test for Foot-And-Mouth Disease Virus Serotype O in Pigs.

Viruses·2025

Same author

Using reverse genetics tool for study of Senecavirus A: pros and cons.

Frontiers in veterinary science·2025

Same author

Pathogenicity of Novel H3 Avian Influenza Viruses in Chickens and Development of a Promising Vaccine.

Viruses·2025

Search research articles

Related Experiment Video

Updated: May 27, 2026

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Virus-like particles: potential veterinary vaccine immunogens.

Fuxiao Liu¹, Shengqiang Ge, Lin Li

¹National Diagnostic Center for Exotic Animal Diseases, China Animal Health and Epidemiology Center, No. 369 Nanjing Road, Qingdao, Shandong 266032, China.

Research in Veterinary Science

|November 22, 2011

Summary

Virus-like particles (VLPs) offer a safe and effective alternative to traditional animal vaccines. This review explores their potential to replace conventional veterinary vaccines, enhancing protection and safety for vaccinated animals.

More Related Videos

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

Related Experiment Videos

Last Updated: May 27, 2026

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

Area of Science:

Veterinary Vaccinology
Biotechnology
Immunology

Background:

Virus-like particles (VLPs) mimic native viruses without genetic material, eliciting strong immune responses.
VLPs are safe and highly immunogenic, leading to successful human vaccines (e.g., Hepatitis B, HPV).
Licensed veterinary VLP vaccines are currently unavailable, despite limitations of conventional animal vaccines.

Purpose of the Study:

To review the current status of virus-like particles (VLPs) as veterinary vaccines.
To discuss the characteristics and challenges of developing VLP-based vaccines for animal viruses.
To highlight the potential of VLPs to overcome limitations of traditional veterinary vaccines.

Main Methods:

Literature review of VLP technology in veterinary applications.
Analysis of VLP immunogenicity, safety, and production methods.
Discussion of challenges and future directions for veterinary VLP vaccine development.

Main Results:

VLPs demonstrate high immunogenicity and safety as vaccine candidates.
Conventional veterinary vaccines (inactivated, live attenuated) have limitations like incomplete inactivation and virulence reversion.
VLP-based vaccines show promise for improved protection and safety in animals.

Conclusions:

VLPs represent a promising platform for next-generation veterinary vaccines.
Addressing challenges in VLP generation is crucial for widespread adoption in animal health.
VLP vaccines have the potential to significantly advance veterinary disease prevention.